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7RESEARCH Open AccessDose-painting intensity-modulated proton therapy
for intermediate- and high-risk meningioma
Indira Madani1,2*, Antony J Lomax1, Francesca Albertini1, Petra Trnková1 and Damien C Weber1,3Abstract
Background: Newly diagnosed WHO grade II-III or any WHO grade recurrent meningioma exhibit an aggressive
behavior and thus are considered as high- or intermediate risk tumors. Given the unsatisfactory rates of disease
control and survival after primary or adjuvant radiation therapy, optimization of treatment strategies is needed.
We investigated the potential of dose-painting intensity-modulated proton beam-therapy (IMPT) for intermediate- and
high-risk meningioma.
Material and methods: Imaging data from five patients undergoing proton beam-therapy were used. The
dose-painting target was defined using [68]Ga-[1,4,7,10-tetraazacyclododecane tetraacetic acid]– d-Phe1,Tyr3-octreotate
([68]Ga-DOTATATE)-positron emission tomography (PET) in target delineation. IMPT and photon intensity-modulated
radiation therapy (IMRT) treatment plans were generated for each patient using an in-house developed treatment
planning system (TPS) supporting spot-scanning technology and a commercial TPS, respectively. Doses of 66 Gy
(2.2 Gy/fraction) and 54 Gy (1.8 Gy/fraction) were prescribed to the PET-based planning target volume (PTVPET) and the
union of PET- and anatomical imaging-based PTV, respectively, in 30 fractions, using simultaneous integrated boost.
Results: Dose coverage of the PTVsPET was equally good or slightly better in IMPT plans: dose inhomogeneity was
10 ± 3% in the IMPT plans vs. 13 ± 1% in the IMRT plans (p = 0.33). The brain Dmean and brainstem D50 were small
in the IMPT plans: 26.5 ± 1.5 Gy(RBE) and 0.002 ± 0.0 Gy(RBE), respectively, vs. 29.5 ± 1.5 Gy (p = 0.001) and 7.5 ± 11.1 Gy
(p = 0.02) for the IMRT plans, respectively. The doses delivered to the optic structures were also decreased with IMPT.
Conclusions: Dose-painting IMPT is technically feasible using currently available planning tools and resulted in dose
conformity of the dose-painted target comparable to IMRT with a significant reduction of radiation dose delivered to
the brain, brainstem and optic apparatus. Dose escalation with IMPT may improve tumor control and decrease
radiation-induced toxicity.
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MeningiomaBackground
Newly diagnosed WHO grade II and III or any WHO
grade recurrent meningioma due to their aggressive be-
havior [1,2] are considered as high- or intermediate-risk
tumors [3]. Surgical excision rarely cures the patient
with these challenging tumors and adjuvant treatment is
needed. When meningioma is not resectable, primary ra-
diation therapy is an alternative. Meningioma patients
can be treated primary or in the adjuvant setting by con-
ventional external beam photon radiotherapy [4], high-* Correspondence: indira.madani@ugent.be
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unless otherwise stated.precision stereotactic radiosurgery [5], stereotactic frac-
tionated radiotherapy [6], or intensity-modulated radi-
ation therapy (IMRT) [7,8], with the latter treatment
modality administrating a substantial dose to non-target
tissues. Meningioma can also be treated with protons
[9]. Radiation doses ≥60 Gy were identified as a prog-
nostic factor for higher local control, particularly when
they were delivered with proton beams [10]. Proton
beam-therapy offers superior dose distributional qual-
ities as compared to X- or gamma-rays, as the dose de-
position occurs in a modulated narrow zone called the
Bragg peak, with no exit dose distal to the target volume.
Dose escalation using proton beam-therapy holds the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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However, higher radiation doses in large target volumes
may increase the risk of radiation-induced toxicity, as re-
ported for stereotactic radiosurgery [13]. One way to
overcome this challenge is to escalate the dose in a frac-
tion of the target volume, which is biologically relevant
for disease control, applying a dose painting paradigm
[14,15]. Dose painting using biological imaging aims at
mapping dose distributions to tumor heterogeneity,
where radioresistant regions within the tumor would re-
ceive higher doses (dose escalation) and radiosensitive
regions would be irradiated to conventional or even
lower (dose de-escalation) radiation doses.
Meningiomas have increased expression of somato-
statin receptors, with the highest expression of sub-
type 2 (SSTR2A) receptors [16,17]. This has led to
suggestions of using positron emission tomography
(PET) [68]Ga-labeled somatostatin analogs - [68]Ga-
[1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraace-
tic-acid]-D-Phe1-Tyr3-octreotide ([68]Ga-DOTATOC)
or [68]Ga-[1,4,7,10-tetraazacyclododecane tetraacetic
acid]– d-Phe1,Tyr3-octreotate ([68]Ga-DOTATATE) –
to improve tumor detection [18,19] and target volume
definition [6,20,21]. [68]Ga-DOTATOC-PET can de-
tect SSTR2A density [22], for which a significant cor-
relation with microvascular density, high histological
grade and proliferation-related Ki-67 antigen (Ki67) of
the tumor has been reported [23]. Because microvascular
density, high histological grade and proliferation are all
unfavorable prognostic factors for meningioma [24,25],
[68Ga]DOTATOC- or DOTATATE-PET-positive regions
within the tumor may represent a target for dose escal-
ation, while the rest of the tumor would receive conven-
tional radiation dose. Several target volumes require
several dose prescriptions that could be done using either
sequential boost or simultaneous integrated boost (SIB),
the latter providing the most conformal dose distributions
with intensity-modulated techniques [26]. Pencil beam
intensity-modulated proton beam-therapy (IMPT) pio-
neered and currently used in Paul Scherrer Institute (PSI),
Villigen, Switzerland allows generation of SIB plans for
dose painting aiming at higher dose prescription inside
the biological image-based contours. In this study we ex-
amined the potential of dose escalation in [68]Ga-DOTA-
TATE-PET-based targets using IMPT as compared to
photon-beam IMRT. We evaluated dose coverage of the
targets and sparing of organs-at-risk (OARs) in dose-
painting plans generated with proton and photon beams.
Material and methods
Imaging and target definition
Imaging data of five patients undergoing proton beam-
therapy in PSI were used in this study. All patients gave
their written informed consent on the use of their datain the institutional board-reviewed study. All patients
were immobilized in supine position with a bite block or
a mask to minimized head movements. Planning com-
puter tomography (CT) scans (HiSpeed DX/I CT scanner,
GE, Chalfont St. Giles, UK) acquired in a treatment plan-
ning position with 2-mm slicing were transferred to a
RayStation treatment planning system, v. 3.99.0.18
(RaySearch Laboratories AB, Stockholm, Sweden) for co-
registration with pre- and post-contrast T1-weighted mag-
netic resonance (MR) and [68]Ga-DOTATATE-PET/CT
scans and delineation of targets and OARs. Dynamic [68]
Ga-DOTATATE-PET/CT was performed prior proton
beam-therapy at a dedicated GE Discovery VCT PET/CT
scanner consisting of a BGO full-ring PET and a 64-slice
or spiral CT or GE Discovery DST PET/CT scanner con-
sisting of LYSO full-ring PET and 16-slice spiral CT, both
in 3D mode. PET data were reconstructed iteratively with
attenuation correction.
Two gross tumor volumes (GTVs) – biological image-
based (GTVPET) and anatomical image-based (GTVCT/
MR) – were the results of auto-segmentation of PET-
scans using 50% of maximum standardized uptake value
(SUVmax) [27] and manual delineation of the macro-
scopic tumor visible on CT and/or magnetic resonance
(MR) scans, respectively. The union of the 2 GTVs re-
sulted in the GTVunion. A margin of 5 mm was added to
the GTVunion to create the union clinical target volume
(CTVunion). The GTVPET and CTVunion were isotropic-
ally expanded with a 3-mm margin to obtain the PET-
based planning target volume (PTVPET) and union PTV
(PTVunion), respectively. Delineated OARs included the
brainstem itself, the brain, the optic chiasm, ipsilateral
optic nerve, retina and lacrimal gland. A 3-mm margin
was added to the brainstem, optic chiasm, optic nerve
and retina to obtain the respective planning organ-at-
risk volumes (PRVs).
Treatment planning and dose prescription
An in-house developed treatment planning system sup-
porting spot-scanning technology on PSI Gantry 1 [28]
was used in IMPT treatment planning. In all but one pa-
tient 4 non-coplanar beams were used whilst 1 patient
was planned with 3 non-coplanar beams. Selection of
gantry and couch angles was based on the PSI Gantry 1
clinical treatment protocol. Initial beam energies were
between 138 and 177 MV for each field. Dose computa-
tions used a proton ray-casting pencil beam model [29]
including heterogeneity corrections [30,31] and allowing
3-dimensional optimization of intensity-modulated pro-
ton fields [32]. All IMPT plans were normalized to the
mean PTVPET dose.
IMRT treatment planning was performed on the
RayStation treatment planning system using a step-
and-shoot technique with 6 MV photons of an Elekta
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were based on 4 individually selected non-coplanar beams.
Final dose computations were done with a collapse cone
convolution superposition dose engine.
We used SIB in our dose prescription. The prescription
doses of 66 Gy (2.2 Gy/fraction) and 54 Gy (1.8 Gy/frac-
tion) were to the PTVPET and PTVunion, respectively, in 30
fractions. The dose of 66 Gy was equivalent to biologically
effective dose (BED2) of 70 Gy in 35 fractions. This dose
level matches the radiation dose in the high-risk arm of
the phase II European Organization for the Research and
Treatment of Cancer (EORTC 22042-26042). We aimed
at planning at least 95% of the prescription dose to 95% of
the PTVPET and PTVunion minus PTVPET and not more
than 107% of the prescription dose to 5% in both PTVs.
Dose inhomogeneity calculated as (D2-D98)/D50 was set
to ≤10% in the PTVPET. Less than 5% of the PRVs of
the brainstem, optic chiasm and optic nerve were allowed
to receive 60 Gy. Less than 5% of the PRV of the retina
were allowed to receive 55 Gy. A median dose to the lacri-
mal gland should not exceed 30 Gy. We used the same
treatment planning objectives in IMPT (applying relative
biological effectiveness factor of 1.1) and IMRT treatment
planning. If a treatment plan did not fulfill dose prescrip-
tion to the brainstem, optic structures (chiasm, nerve and
retina) and lacrimal gland, we would give priority to dose-
volume constraints of those OARs aiming at the prescrip-
tion dose to the CTV. The D2 (a surrogate of maximum
dose), D50, and D98 (a surrogate of minimum dose) are
dose levels on the dose-volume histograms (DVHs) above
which lay 2%, 50%, and 98% of the contoured volume,
respectively.
Statistics
We analyzed individual DVHs and 3-dimensional dose
distributions and compared dose-volume metrics of
IMPT and IMRT treatment plans using a paired T-test
considering p < 0.05 significant. Statistical analysis was
done using a Statistical Package for the Social Sciences
(SPSS) software, version 20 (IBM, NY).
Results
Patient characteristics are presented in Table 1. None of
the patients were irradiated previously. Four patientsTable 1 Patient characteristics
Patient N. Gender Age (year) T
1 Female 60 P
2 Female 45 S
3 Female 38 F
4 Male 75 F
5 Female 64 F
*Combined with embolization.had 1 PTVPET and 1 patient had 2 PTVsPET. The median
volume of the PTVPET and PTVunion was 4.3, range 0.31-
52.1 cm3 and 99.5, range 18.1-199.2 cm3, respectively.
DVHs and dose distributions of IMPT and IMRT plans
for patient 1 are presented in Figure 1 and Figure 2.
Compiled dose-volume metrics of all patients are given
in Table 2. Treatment-planning objectives were fulfilled
in all IMPT and IMRT plans except one case (patient
2), where IMPT failed to spare the ipsilateral lacrimal
gland. Dose coverage of the PTVPET did not differ be-
tween the two methods with dose inhomogeneity of
10% (IMPT) (range 5.5-15.5%) and 13% (IMRT) (range
7.0-33.2%) on average.
In one patient with the largest PTVPET abutting optic
structures dose inhomogeneity was 15% and 33% in the
IMPT and IMRT plan, respectively. Dose inhomogen-
eity achieved with both IMPT and IMRT was still 10%
or lower, when there were two dose-painted targets in-
side the PTVunion (patient 3). Dose inhomogeneity was
slightly lower in the PTVunion in IMPT plans as com-
pared to IMRT – 28% vs. 43%. Nevertheless, Dmean of
26.5 ± 1.5 Gy to the brain was significantly less in the
IMPT plans than 29.5 ± 1.5 Gy(RBE) in the IMRT plans
(p = 0.001; Table 2). A significant difference in D50 to
the brainstem was observed in the IMPT plans - 0.002 ±
0.0 Gy(RBE) vs. 7.5 ± 11.1 Gy in the IMRT plans (p = 0.02;
Table 2). There was only one patient in our study (patient
2), who required sparing the optic structures and lacrimal
gland. Although dose-volume constraints to the optic
nerve and retina were met with IMPT, D50 exceeded a
30 Gy limit set for the lacrimal gland - 40.7 Gy(RBE) vs.
14.6 Gy obtained by IMRT. D5 to the optic chiasm and
brainstem were 1.5 and 10 times less in IMPT plans than
in IMRT plans for this patient.
Discussion
Until the results of the EORTC 22042-26042 and Radi-
ation Therapy Oncology Group 0539 studies [3,33] are
available, there is no agreement on what radiation dose
level should be prescribed for WHO grade II-III or re-
current meningioma; however, higher doses are believed
to be more effective. Several studies examine the benefits
of dose escalation – either by increasing the number of
fractions with 3-dimensional (3D) conformal photon,umor location WHO grade Prior surgery
arasaggital I 2*
phenoid I 1
alx I 2
alx II 2*
alx II 1
Figure 1 Dose-volume histograms of intensity-modulated proton-beam therapy (IMPT) in solid and photon intensity-modulated radiation
therapy (IMRT) in dash for a patient with a recurrent WHO grade I parasagittal meningioma. The brainstem in the IMPT plan receives a
zero dose.
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sequential boost with photon 3D-conformal radiation
therapy/IMRT [33], IMPT and carbon-ion radiation
therapy [34,35]. A few studies demonstrated clinical
feasibility of dose escalation combining photon and pro-
ton beams [10-12]. Hug et al. showed significant im-
provement in the local control and survival rates atFigure 2 Dose distributions in the axial plane of the intensity-modulate
radiation therapy (IMRT) plans for the same patient. The union planning
and in blue (IMRT).doses ≥60 cobalt gray equivalent (CGE) in 1.8-2.0 CGE/
fraction [10]. Boskos et al. treated 24 patients after sur-
gery for atypical and malignant meningioma to a median
total dose of 68 CGE in 1.8-2.0 CGE/fraction [11]. They
reported significant association between increase in
overall survival and doses >60 CGE. Chan et al. escalated
radiation dose to 68.4 and 72 Gy (RBE) in 1.8 Gy (RBE)/d proton-beam therapy (IMPT) and photon intensity-modulated
target volume (PTVunion) minus the PET-based PTV is in light green (IMPT)
Table 2 Dose-volume metrics (mean dose ± standard
deviation) of intensity-modulated proton beam-therapy
(IMPT) and intensity-modulated photon radiotherapy
(IMRT) treatment plans
IMPT IMRT p-value
GTVPET
D98 (GyRBE) 65.3 ± 1.3 63.8 ± 2.8 0.16
D95 (GyRBE) 65.7 ± 1.1 64.4 ± 2.4 0.14
D50 (GyRBE) 67.2 ± 0.9 67.1 ± 1.0 0.67
D2 (GyRBE) 69.0 ± 1.0 69.9 ± 1.9 0.37
PTVPET
D98 (GyRBE) 62.3 ± 1.4 60.1 ± 5.7 0.28
D95 (GyRBE) 63.3 ± 0.7 62.1 ± 2.5 0.19
D50 (GyRBE) 66.2 ± 0.3 65.5 ± 1.2 0.15
D2 (GyRBE) 68.8 ± 0.9 68.6 ± 0.9 0.73
Homogeneity 0.10 ± 0.03 0.13 ± 0.1 0.33
GTVunion
D98 (GyRBE) 56.5 ± 2.9 56.0 ± 3.8 0.51
D95 (GyRBE) 57.7 ± 3.0 57.1 ± 3.3 0.44
D50 (GyRBE) 62.3 ± 4.6 61.5 ± 3.6 0.48
D2 (GyRBE) 67.9 ± 1.4 67.9 ± 1.3 0.89
CTVunion
D98 (GyRBE) 54.0 ± 2.2 48.7 ± 9.0 0.16
D95 (GyRBE) 55.1 ± 2.1 53.5 ± 3.8 0.14
D50 (GyRBE) 60.1 ± 3.3 58.7 ± 2.5 0.23
D2 (GyRBE) 67.1 ± 1.4 67.1 ± 1.4 0.99
PTVunion
D98 (GyRBE) 50.0 ± 13.6 42.0 ± 12.3 0.18
D95 (GyRBE) 51.8 ± 7.4 48.1 ± 6.6 0.22
D50 (GyRBE) 58.3 ± 2.2 57.1 ± 2.0 0.26
D2 (GyRBE) 66.5 ± 1.9 66.6 ± 1.7 0.96
Homogeneity 0.28 ± 0.04 0.43 ± 0.22 0.15
Brain
D2 (GyRBE) 42.1 ± 24.6 54.3 ± 7.2 0.34
Dmean (GyRBE) 26.5 ± 1.5 29.5 ± 1.5 0.001
Brainstem
D5 (GyRBE) 0.6 ± 1.4 11.0 ± 13.5 0.13
D50 (GyRBE) 0.002 ± 0.0 7.5 ± 11.1 0.02
Optic chiasm
D5 (GyRBE) 28.1 41.6 -
Ipsilateral optic nerve
D5 (GyRBE) 59.1 59.4 -
Abbreviations: GTV = gross tumor volume; PTV = planning target volume; CTV =
clinical target volume; Dx = dose level on the dose-volume histograms, above
which lay x% of the contoured volume.
Doses to the optic chiasm and ipsilateral optic nerve are reported for
one patient.
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ingioma, respectively [12]. Treatment was well tolerated
without grade 3 or greater toxicity. In a planning study
comparing IMRT, IMPT and carbon-ion radiation ther-
apy using sequential boost, dose escalation in the
boosted PTV (median volume 94 ± 46 cm3) up to 68 Gy
(RBE) in 2 Gy (RBE)/fraction was possible in 2 out of
10 meningioma patients, all planned to 60 Gy (RBE)
[34]. Planning to higher doses was limited by tolerance
of abutting OARs. We believe that IMPT using SIB can
combine many of the benefits of these other treatment
approaches, to yield excellent dose coverage of the target,
superior sparing of critical OARs, such as the brainstem,
brain and optic apparatus (Table 2), shortened treatment
time and advantages of hypofractionation.
Into best of our knowledge, this is the first paper
evaluating IMPT using SIB for intermediate- and high-
risk meningioma [36]. In this study we demonstrated
technical feasibility of dose-painting IMPT with the
planning tools currently in use at PSI. It is easy to inte-
grate a boost of 2.2 Gy (RBE)/fraction into convention-
ally - 1.8 Gy (RBE)/fraction - fractionated IMPT. These
SIB IMPT plans can be implemented in clinical use im-
mediately after dosimetric verification.
IMPT and IMRT plans have excellent dose coverage
of the dose-painted target: dose inhomogeneity is on
average 10% and 13%, respectively. However, the high
conformity of the IMRT plans has been reached at the
cost of larger volumes of the brain and brainstem re-
ceiving intermediate- to low doses. This is in contrast
to the IMPT plans where there was no or minimal dose
to the brain and brainstem (Table 2). There was a sig-
nificant reduction of Dmean to the brain and D50 to the
brainstem obtained with proton beams for all plans
(Table 2). This may be translated into better neurological
and cognitive outcomes, particularly if non-involved brain
areas responsible for “key” brain functions, e.g., the
hippocampus, are included in the IMPT optimization.
With the perspective of increased disease control
resulting from dose escalation, preservation of patients’
neurocognitive functions and quality-of-life becomes of
higher importance.
Nevertheless, the study shows that pencil beam spot size
is an important consideration. One of the shortcomings of
IMPT planned for PSI Gantry 1 was overdosage of the lac-
rimal gland, due to large lateral penumbra of the proton
beams from that treatment device. Because of the lateral
pencil beam width, a small, superficially located gland
overlapping the PTV could not be spared as good as with
IMRT, though there were higher doses to the brain, brain-
stem and optic chiasm in IMRT plans. Therefore, using
proton beams with smaller lateral width are important to
ensure sharper dose gradients and thus better sparing of
small OARs in the immediate vicinity to the target [37].
Madani et al. Radiation Oncology  (2015) 10:72 Page 6 of 7Using [68]Ga-DOTATOC- or DOTATATE-PET in tar-
get volume determination leads to target volume modifi-
cation in approximately 70% of the patients [6,21] with a
smaller target volume in 35-50% of the patients [6,20].
One challenge is that the methodology of PET-based tar-
get volume segmentation is not standardized and most
investigators delineate the target manually by adjusting
the window of the PET scans to the GTV visible on CT
and/or MR. To avoid drawbacks of manual delineation
we have chosen to perform threshold-based auto-
segmentation of the GTVPET. In absence of consensus
guidelines for the cut-off SUV values for PET-based seg-
mentation of meningioma, we have selected 50% SUV-
max for our PET scans. The resulting PTVPET volumes
are quite small, with a median of 4.3 cm3. Although no
limits have been set on the volume for dose painting, we
believe that escalating dose in smaller volumes is a safer
strategy. Nevertheless, uncertainties of our delineation
strategy warrants further investigation.
Conclusions
Dose-painting IMPT using SIB is technically feasible
with the currently available tools at our institution.
IMPT plans resulted in excellent dose coverage of the
dose-painted PTVPET and PTVCT/MR at minimal or no
dose to the brain, brainstem and optic apparatus that
could be translated into improved disease control and
radiation-induced toxicity.
Abbreviations
BED: Bxiologically effective dose; CGE: Cobalt gray equivalent; CT: Computer
tomography; DVH: Dose-volume histogram; EORTC: European Organization for
the Research and Treatment of Cancer; [68]Ga-DOTATATE: [68] Ga-[1,4,7,10-
tetraazacyclododecane tetraacetic acid]– d-Phe1,Tyr3-octreotate; [68]Ga-
DOTATOC: [68] Ga-[1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic-acid]-
D-Phe1-Tyr3-octreotide; GTV: Gross tumor volume; IMPT: Intensity-modulated
proton beam-therapy; IMRT: Intensity-modulated radiation therapy;
Ki67: proliferation-related Ki-67 antigen; MR: Magnetic resonance imaging;
OAR: Organ-at-risk; PSI: Paul Scherrer Institute; PET: Positron emission
tomography; PRV: Planning organ-at-risk volume; PTV: Planning target volume;
RBE: Relative biological effectiveness; SIB: Simultaneous integrated boost;
SSTR2A: Somatostatin receptor subtype 2; SUV: Standardized uptake value;
WHO: World Health Organization.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
Concept and design: IM, DW; provision of study material: DW; collection and
assembly of data: IM, AL, FA, PT; data analysis and interpretation: IM, AL,
manuscript writing: IM; all authors read and approved the final manuscript.
Acknowledgement
The work was sponsored by the Cancer Plan, Action 30 and financed by the
Federal Public Service of Health, Food Chain Safety and Environment,
Belgium. We would like to thank RaySearch Laboratories AB, Stockholm,
Sweden for providing access to the RayStation treatment planning system.
Author details
1Center for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland.
2Ghent University, Ghent, Belgium. 3Department of Radiation Oncology,
University Hospital of Zürich, Zürich, Switzerland.Received: 19 November 2014 Accepted: 17 March 2015
References
1. Miralbell R, Linggood RM, De Las Monte S, Convery K, Munzenrider JE,
Mirimanoff RO. The role of radiotherapy in the treatment of subtotally
resected benign meningiomas. J Neuro-Oncol. 1992;13:157–64.
2. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ.
Meningiomas. In: Kleihues P, Cavenee WK, editors. Pathology and genetics
of tumours of the nervous system: World Health Organisation classification
of tumours. Lyon: IARC Press; 2000. p. 176–84.
3. Weber DC, Lovblad KO, Rogers L. New pathology classification, imagery
techniques and prospective trials for meningiomas: the future looks bright.
Curr Opin Neurol. 2010;23(6):563-70.
4. Kallio M, Sankila R, Hakulinen T, Jääskeläinen J. Factors affecting operative
and excess long-term mortality in 935 patients with intracranial
meningioma. Neurosurgery. 1992;31:2–12.
5. Stafford SL, Pollock BE, Foote RL, Link MJ, Gorman DA, Schomberg PJ, et al.
Meningioma radiosurgery: tumor control, outcomes, and complications
among 190 consecutive patients. Neurosurgery. 2001;49:1029–37.
6. Milker-Zabel S, Zabel-du Bois A, Henze M, Huber P, Schulz-Ertner D, Hoess A,
et al. Improved target volume definition for fractionated stereotactic
radiotherapy in patients with intracranial meningiomas by correlation of CT,
MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222–7.
7. Uy NW, Woo SY, Teh BS, Mai WY, Carpenter LS, Chiu JK, et al. Intensity-
modulated radiation therapy (IMRT) for meningioma. Int J Radiat Oncol Biol
Phys. 2002;53:1265–70.
8. Milker-Zabel S, Zabel-du Bois A, Huber P, Schlegel W, Debus J. Intensity-
modulated radiotherapy for complex-shaped meningioma of the skull base:
long-term experience of a single institution. Int J Radiat Oncol Biol Phys.
2007;68:858–63.
9. Weber DC, Schneider R, Goitein G, Koch T, Ares C, Geismar JH, et al. Spot
scanning-based proton therapy for intracranial meningioma: long-term results
from the Paul Scherrer Institute. Int J Radiat Oncol Biol Phys. 2012;83:865–71.
10. Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS, Hedley-Whyte ET,
et al. Management of atypical and malignant meningiomas: role of high-
dose, 3D-conformal radiation therapy. J Neurooncol. 2000;48:151–60.
11. Boskos C, Feuvret L, Noel G, Habrand JL, Pommier P, Alapetite C, et al.
Combined proton and photon conformal radiotherapy for intracranial
atypical and malignant meningioma. Int J Radiat Oncol Biol Phys.
2009;75:399–406.
12. Chan AW, Bernstein KD, Adams JA, Parambi RJ, Loeffler JS. Dose escalation
with proton radiation therapy for high-grade meningiomas. Technol Cancer
Res Treat. 2012;11:607–14.
13. Kollová A, Liscák R, Novotný Jr J, Vladyka V, Simonova G, Janouskova L. Gamma
Knife surgery for benign meningioma. J Neurosurg. 2007;107:325–36.
14. Ling CC, Humm J, Larson S, Amols H, Fuks Z, Leibel S, et al. Towards
multidimensional radiotherapy (MD-CRT): biological imaging and biological
conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–60.
15. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by
numbers. Lancet Oncol. 2005;6:112–7.
16. Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R, et al. Expression of
somatostatin receptor subtypes in human brain tumors. Int J Cancer.
1998;76:620–7.
17. Arena S, Barbieri F, Thellung S, Pirani P, Corsaro A, Villa V, et al. Expression of
somatostatin receptor mRNA in human meningiomas and their implication
in in vitro antiproliferative activity. J Neurooncol. 2004;66:155–66.
18. Henze M, Schuhmacher J, Hipp P, Kowalski J, Becker DW, Doll J, et al. PET
imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-
octreotide: first results in patients with meningiomas. J Nucl Med.
2001;42:1053–6.
19. Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE,
et al. Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT
and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39:1409–15.
20. Gehler B, Paulsen F, Oksüz MO, Hauser TK, Eschmann SM, Bares R, et al.
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat
Oncol. 2009;4:56.
21. Graf R, Nyuyki F, Steffen IG, Michel R, Fahdt D, Wust P, et al. Contribution of
68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas
treated with stereotactic radiation therapy. Int J Radiat Oncol Biol Phys.
2013;85:68–73.
Madani et al. Radiation Oncology  (2015) 10:72 Page 7 of 722. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss
LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide
kinetics in patients with meningiomas. J Nucl Med. 2005;46:763–9.
23. Barresi V, Alafaci C, Salpietro F, Tuccari G. Sstr2A immunohistochemical
expression in human meningiomas: is there a correlation with the
histological grade, proliferation or microvessel density? Oncol Rep.
2008;20:485–92.
24. Barresi V, Cerasoli S, Vitarelli E, Tuccari G. Density of microvessels positive for
CD105 (endoglin) is related to prognosis in meningiomas. Acta
Neuropathol. 2007;114:147–56.
25. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in
meningiomas: a clinicopathologic study of 116 patients, with grading
implications. Cancer. 1999;85:2046–56.
26. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological considerations
in the design of fractionation strategies for intensity-modulated radiation
therapy of head and neck cancers. Int J Radiat Oncol Biol Phys. 2000;46:619–30.
27. Vees H, Senthamizhchelvan S, Miralbell R, Weber DC, Ratib O, Zaidi H.
Assessment of various strategies for 18 F-FET PET-guided delineation of
target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging.
2009;36:182–93.
28. Pedroni E, Bacher R, Blattmann H, Bohringer T, Coray A, Lomax A, et al. The
200-MeV proton therapy project at the Paul Scherrer Institute: Conceptual
design and practical realization. Med Phys. 1995;22:37–53.
29. Scheib S, Pedroni E. Dose calculation and optimization for 3D conformal
voxel scanning. Radiat Environ Biophys. 1992;31:251–6.
30. Schaffner B, Pedroni E, Lomax A. Dose calculation models for proton
treatment planning using a dynamic beam delivery system: An attempt to
include density heterogeneity effects in the analytical dose calculation. Phys
Med Biol. 1999;44:27–41.
31. Petti PL. Differential-pencil-beam dose calculations for charged particles.
Med Phys. 1992;19:137–49.
32. Lomax A. Intensity modulation methods for proton radiotherapy. Phys Med
Biol. 1999;44:185–205.
33. Coskun M, Straube W, Hurkmans CW, Melidis C, de Haan PF, Villa S, et al.
Quality assurance of radiotherapy in the ongoing EORTC 22042-26042 trial
for atypical and malignant meningioma: results from the dummy runs and
prospective individual case Reviews. Radiat Oncol. 2013;8:23.
34. Mock U, Georg D, Solkner L, Suppan C, Vatnitsky SM, Flechl B, et al.
Assessment of improved organ at risk sparing for meningioma: light ion
beam therapy as boost versus sole treatment option. Radiother Oncol.
2014;111:451–6.
35. Combs SE, Welzel T, Habermehl D, Rieken S, Dittmar JO, Kessel K, et al.
Prospective evaluation of early treatment outcome in patients with
meningiomas treated with particle therapy based on target volume
definition with MRI and 68Ga-DOTATOC-PET. Acta Oncol. 2013;52:514–20.
36. Zhu XR, Poenisch F, Li H, Sahoo N, Wu RY, Li X, et al. A single-field
integrated boost treatment planning technique for spot scanning proton
therapy. Radiat Oncol. 2014;9:202.
37. Lehde A. Initial clinical evaluation of PSIPLAN2 and Gantry2: a planning
comparison study in proton therapy. Master thesis. Bern University of
Applied Sceince. 2013Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
